Stratasys Ltd (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) announced a joint development and commercialization agreement to develop a human tissue and organ biofabrication solution. The first project focuses on developing an industrial solution for CollPlant’s regenerative breast implant program.
Stratasys is a leading provider of 3D printing solutions, while CollPlant develops innovative technologies and products for regenerative and aesthetic medicine. The new Bioprinter combines Stratasys’ precise P3 3D printing technology with CollPlant’s bio-inks to create advanced breast implants. These are designed to regenerate a person’s natural breast tissue without triggering immune responses, offering a potentially revolutionary alternative for aesthetic and reconstructive procedures.
“Through this partnership with CollPlant, we have an important opportunity to transform healthcare with bioprinting to improve the lives of patients undergoing breast augmentation or reconstruction procedures,” said Stratasys CEO Dr. Yoav Zeif. “This agreement is well-aligned with our strategy to deliver complete solutions for high-growth industry applications with our ecosystem of partners, and the production scale and precision 3D printing capabilities of Stratasys’ P3 Programmable Photopolymerization technology are a particularly strong fit for bioprinting applications. We believe that partnering with CollPlant will enable us to accelerate the industrialization of bioprinting for regenerative medicine, and we look forward to collaborating towards the successful commercialization of CollPlant’s novel regenerative breast implants and beyond.”
Yehiel Tal, CEO of CollPlant, commented, “Stratasys is leading in additive manufacturing and we are excited to collaborate with them on this transformative initiative. The P3 technology allows printing with high resolution and process control, and we believe that the combined, pioneering technologies of both companies will streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants and other potential tissues and organs. We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer.”
CollPlant announced in January 2023 that it had completed a successful large animal study for its regenerative breast implants. The preclinical study showed progressive stages of tissue regeneration after three months. Based on these positive results, CollPlant plans to conduct a follow-up large animal study in the second half of 2023 to support subsequent human studies and future commercialization of the product.
Find out more about Stratasys at stratasys.com.
For more information about CollPlant, please visit collplant.com.
Subscribe to our Newsletter
3DPResso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
